keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/29142181/treatment-strategy-for-standard-dose-proton-pump-inhibitor-resistant-reflux-esophagitis
#1
Katsuhiko Iwakiri
Reflux esophagitis is characterized by excessive esophageal acid exposure. To treat reflux esophagitis, it is necessary to reduce excessive esophageal acid exposure to within the normal range. The first-line drug for the treatment of reflux esophagitis is a standard-dose proton-pump inhibitor (PPI), which is also recommended by the Evidence-based Clinical Practice Guidelines 2015 for gastroesophageal disease of the Japanese Society of Gastroenterology. It has been reported that the response to a standard dose of PPI in patients with mild reflux esophagitis is 90-100%, and that in patients with severe reflux esophagitis is 80-85%...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/29132551/vonoprazan-treatment-improves-gastrointestinal-symptoms-in-patients-with-gastroesophageal-reflux-disease
#2
Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto
The effects of vonoprazan, a new potassium-competitive acid blocker, on gastroesophageal reflux disease (GERD) symptom are not fully elucidated. The aim of this study is to determine the effect of vonoprazan on GERD and associated gastrointestinal symptoms. We retrospectively reviewed 88 Helicobacter pylori negative patients with GERD treated with vonoprazan 10 mg daily. Symptoms were evaluated using the Izumo scale, which reflects quality of life related to various abdominal symptoms. The rates of improvement and resolution of GERD symptoms were 86% (76/88) and 57% (50/88), respectively...
December 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29112902/development-of-a-stability-indicating-hplc-method-for-simultaneous-determination-of-ten-related-substances-in-vonoprazan-fumarate-drug-substance
#3
Zhiqiang Luo, Aoxue Liu, Yang Liu, Guopeng Wang, Xinjing Chen, Hao Wang, Mengwei Li, Haili Zhang, Yanhua Qiu, Huaqiang Zhai
Vonoprazan fumarate is a novel potassium-competitive acid blocker for the treatment of acid-related diseases. In the present study, a simple, fast, and economic reversed-phase liquid chromatography (LC) method was developed for the analysis of ten related substances (raw materials, by-products and degradants) in vonoprazan fumarate. The optimized separation was performed on a Phenomenex Kinetex EVO C18 (250mm×4.6mm, 5.0μm) column. The mobile phase consisted of (A) 0.03M sodium phosphate buffer (pH adjusted to 6...
November 4, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29057719/changes-in-gefitinib-erlotinib-and-osimertinib-pharmacokinetics-under-various-gastric-ph-levels-following-oral-administration-of-omeprazole-and-vonoprazan-in-rats
#4
Osamu Yasumuro, Shinya Uchida, Yasuharu Kashiwagura, Ayae Suzuki, Shimako Tanaka, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki
1. Although drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and gastric acid-suppressing medications (AS) are considered clinically significant, there is limited data regarding the influence of various gastric pH conditions on the pharmacokinetics of EGFR-TKIs. We aimed to clarify the changes in the pharmacokinetics of the EGFR-TKIs, gefitinib, erlotinib, and osimertinib, due to the changes in gastric pH after administration of omeprazole or vonoprazan. 2. Omeprazole (10 - 100 mg/kg, p...
October 21, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/28988197/vonoprazan-prevents-ulcer-recurrence-during-long-term-nsaid-therapy-randomised-lansoprazole-controlled-non-inferiority-and-single-blind-extension-study
#5
Yuji Mizokami, Kazunori Oda, Nobuo Funao, Akira Nishimura, Satoshi Soen, Takashi Kawai, Kiyoshi Ashida, Kentaro Sugano
OBJECTIVE: To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use. DESIGN: A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter, single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence...
October 7, 2017: Gut
https://www.readbyqxmd.com/read/28986609/comparison-of-effect-of-an-increased-dosage-of-vonoprazan-versus-vonoprazan-plus-lafutidine-on-gastric-acid-inhibition-and-serum-gastrin
#6
Takahiro Suzuki, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta
BACKGROUND: Vonoprazan, a novel potassium-competitive acid blocker, elicits potent acid inhibition and hypergastrinemia at a dose of 20 mg. Its recommended maintenance dose for gastro-esophageal reflux disease is 10 mg, which is sometimes insufficient for preventing nocturnal acid breakthrough (NAB). Concomitant use of a histamine 2 receptor antagonist (H2RA) is effective for NAB. However, further acid inhibition by addition of H2RA has concern of hypergastrinemia again. Lafutidine (H2RA) is known to stimulate somatostatin release...
October 6, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28894571/vonoprazan-10-mg-daily-is-effective-for-the-treatment-of-patients-with-proton-pump-inhibitor-resistant-gastroesophageal-reflux-disease
#7
Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yasutoshi Kobayashi, Alan Kawarai Lefor, Hironori Yamamoto
Gastroesophageal reflux disease (GERD) is commonly treated by primary care physicians. Although proton pump inhibitors (PPI) have been the mainstay of GERD treatment for two decades, in some patients GERD is refractory to standard dose PPI for more than eight weeks and is referred to as PPI-resistant GERD. Vonoprazan, a novel competitive acid blocker, became available in Japan for the treatment of patients with GERD, and has greater acid inhibition than existing PPIs. The aim of the present study was to determine the effect of vonoprazan 10 mg daily on PPI-resistant GERD...
September 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28891137/treatment-of-helicobacter-pylori-infection-2017
#8
REVIEW
Anthony O'Connor, Dominique Lamarque, Javier P Gisbert, Colm O'Morain
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second-line setting, an increasing number of studies this year have shown excellent efficacy in first-line therapy. The efficacy of bismuth as a second-line after sequential and concomitant therapy was particularly noteworthy...
September 2017: Helicobacter
https://www.readbyqxmd.com/read/28884937/a-japanese-population-based-meta-analysis-of-vonoprazan-versus-ppi-for-helicobacter-pylori-eradication-therapy-is-superiority-an-illusion
#9
REVIEW
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, Hong Ling Wang
BACKGROUND: Vonoprazan (VPZ) is a novel acid suppressant that has been used in Helicobacter pylori (H. pylori) eradication therapies in recent years. However, the efficacy and safety of VPZ vs proton-pump inhibitor (PPI) in H. pylori eradication therapies remain controversial. OBJECTIVE: To perform a meta-analysis in order to assess the efficacy and safety of VPZ vs PPI for H. pylori eradication. MATERIALS AND METHODS: The PubMed, EMBASE, and Cochrane Library databases were searched up to July 10, 2017, for relevant randomized controlled trials (RCTs) and nonrandomized clinical studies (NRCTs)...
September 8, 2017: Helicobacter
https://www.readbyqxmd.com/read/28875498/comparative-study-of-effects-of-vonoprazan-and-esomeprazole-on-anti-platelet-function-of-clopidogrel-or-prasugrel-in-relation-to-cyp2c19-genotype
#10
Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura, Hiroaki Miyajima, Takahisa Furuta
Drug-drug interaction between anti-acid and anti-platelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole and vonoprazan. Using P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the anti-platelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers [14 CYP2C19 homo-extensive (homo-EMs), 9 hetero-extensive (hetero-EMs), and 8 poor metabolizers (PMs)]...
September 5, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28845910/successful-eradication-of-helicobacter-pylori-with-a-herbal-medicine-goshuyuto-wu-zhu-yu-tang-plus-rabeprazole-after-failure-of-triplet-therapy-with-vonoprazan-a-report-of-three-cases
#11
Yutaka Nagata, Kazuhiko Nagasaka, Syunpei Koyama, Mai Murase, Minoru Saito, Toshinori Yazaki, Nobutoshi Komatsu, Takayuki Murase, Toshiki Uehara, Norihide Taniuchi
Vonoprazan, a potassium-competitive acid blocker, is used as a substitute drug for conventional proton pump inhibitors. Recently, vonoprazan has been applied for eradication of H. pylori (HP) infection, and the efficacies of vonoprazan-based triple therapy against HP infection have already been reported. However, treatment sometimes fails in the primary and/or secondary triplet eradication therapy, including with the use of vonoprazan for HP infection. We experienced three cases of refractory HP infection. They were treated with eradication therapy for HP infection with chronic gastritis...
August 28, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28814829/antibiotic-susceptibility-heteroresistance-and-updated-treatment-strategies-in-helicobacter-pylori-infection
#12
REVIEW
Maria Teresa Mascellino, Barbara Porowska, Massimiliano De Angelis, Alessandra Oliva
In this review, we discuss the problem of antibiotic resistance, heteroresistance, the utility of cultures and antibiotic susceptibility tests in Helicobacter pylori (Hp) eradication, as well as the updated treatment strategies for this infection. The prevalence of antibiotic resistance is increasing all over the world, especially for metronidazole and clarithromycin, because of their heavy use in some geographical areas. Heteroresistance (simultaneous presence of both susceptible and resistant strains in different sites of a single stomach) is another important issue, as an isolate could be mistakenly considered susceptible if a single biopsy is used for antimicrobial tests...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28806959/second-line-therapy-for-helicobacter-pylori-eradication-causing-antibiotic-associated-hemorrhagic-colitis
#13
Kazuyuki Tanaka, Mikihiro Fujiya, Aki Sakatani, Shugo Fujibayashi, Yoshiki Nomura, Nobuhiro Ueno, Shin Kashima, Takuma Goto, Junpei Sasajima, Kentaro Moriichi, Toshikatsu Okumura
OBJECTIVE: Helicobacter pylori (H. pylori) eradication rarely develops into antibiotic-associated hemorrhagic colitis (AAHC), in which the etiology of colitis remains unclear. We herein report a rare case of AAHC caused by second-line therapy for H. pylori eradication. RESULTS: A 65-year-old female was administered second-line therapy for H. pylori composed of 1500 mg of amoxicillin, 500 mg of metronidazole and 40 mg of vonoprazan for 7 days because of first-line therapy failure...
August 14, 2017: Annals of Clinical Microbiology and Antimicrobials
https://www.readbyqxmd.com/read/28776748/editorial-replacing-standard-proton-pump-inhibitors-with-vonoprazan-may-breathe-new-life-into-triple-therapy-for-helicobacter-pylori
#14
EDITORIAL
A G Fraser
No abstract text is available yet for this article.
September 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28776746/editorial-replacing-standard-proton-pump-inhibitors-with-vonoprazan-may-breathe-new-life-into-triple-therapy-for-helicobacter-pylori-authors-reply
#15
EDITORIAL
Y S Jung, E H Kim, C H Park
No abstract text is available yet for this article.
September 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28776141/vonoprazan-based-helicobacter-pylori-eradication-therapy-time-to-get-kompetitive
#16
EDITORIAL
Eun Hye Kim, Chan Hyuk Park
No abstract text is available yet for this article.
November 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28664410/efficacy-of-vonoprazan-based-triple-therapy-for-helicobacter-pylori-eradication-a-multicenter-study-and-a-review-of-the-literature
#17
REVIEW
Hiroki Tanabe, Katsuyoshi Ando, Kiichi Sato, Takahiro Ito, Mitsuru Goto, Tomonobu Sato, Akihiro Fujinaga, Toru Kawamoto, Tatsuya Utsumi, Nobuyuki Yanagawa, Eiichiro Ichiishi, Takaaki Otake, Yutaka Kohgo, Yoshiki Nomura, Nobuhiro Ueno, Hiroko Sugano, Shin Kashima, Kentaro Moriichi, Mikihiro Fujiya, Toshikatsu Okumura
BACKGROUND: Eradication therapies for Helicobacter pylori infection are advancing as new acid inhibitory reagents approved. The aim of this study was to assess the efficacy and safety of vonoprazan-based triple treatment. MATERIALS AND METHODS: Triple therapy with vonoprazan and two antibiotics (amoxicillin and clarithromycin or metronidazole) received focus in this analysis. We performed a multicenter retrospective study of patients who received vonoprazan-based eradication therapy between February 2015 and February 2016 and conducted a review of the literature...
November 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28662503/the-effects-of-switching-to-vonoprazan-a-novel-potassium-competitive-acid-blocker-on-gastric-acidity-and-reflux-patterns-in-patients-with-erosive-esophagitis-refractory-to-proton-pump-inhibitors
#18
Hiroshi Yamashita, Atsushi Kanamori, Chise Kano, Hiroki Hashimura, Kei Matsumoto, Masahiro Tsujimae, Tetsuya Yoshizaki, Kenji Momose, Daisuke Obata, Takaaki Eguchi, Mikio Fujita, Akihiko Okada
BACKGROUND/AIM: The effects of vonoprazan and proton pump inhibitors (PPIs) in patients with reflux esophagitis (RE) have not yet been compared using multichannel intraluminal impedance-pH (MII-pH). METHODS: A total of 8 patients with persistent gastric mucosal injury, despite completing an 8-week standard PPI therapy, were enrolled in the study. While they were on standard PPI therapy, the baseline values of reflux parameters, holding time ratio (HTR) of gastric pH >4, and esophageal pH <4 were obtained by using 24 h MII-pH monitoring...
2017: Digestion
https://www.readbyqxmd.com/read/28657473/vonoprazan-fumarate-for-the-management-of-acid-related-diseases
#19
REVIEW
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli, Edoardo Savarino
Proton pump inhibitors (PPIs) display a number of limitations and unmet clinical needs that have prompted the development of novel drugs to improve the outcomes of acid-related diseases, including the eradication of H. pylori. In this context, a new synthesized potassium-competitive acid blocker (P-CAB), vonoprazan, showed higher suppression of gastric acid secretion. Areas covered: This review discusses the current knowledge regarding the efficacy of vonoprazan in the treatment of acid-related diseases, with a particular focus on its use in Helicobacter pylori eradication...
August 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28584402/effects-of-patient-age-and-choice-of-antisecretory-agent-on-success-of-eradication-therapy-for-helicobacter-pylori-infection
#20
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima
The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB...
May 2017: Journal of Clinical Biochemistry and Nutrition
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"